Life
Briefing: FDA’s Evolving View of What Makes a ‘Breakthrough’ Device
Strategic angle: An analysis of AI-powered devices that received the FDA's 'breakthrough' label.
Editorial Staff
1 min read
Updated 15 days ago
The FDA has been reassessing the criteria that qualify devices for its 'breakthrough' designation, particularly in the context of AI-powered technologies.
Recent studies, including those on AI scribes, illustrate the potential for these devices to enhance clinical efficiency and accuracy, which may influence regulatory decisions.
Understanding these evolving criteria is crucial for stakeholders in medical technology, as it could affect future device development and market entry strategies.